Angiocrine Bioscience, Inc.

Upper East Side biotech ventures often cluster near research hospitals, where lab space meets clinical urgency. Angiocrine Bioscience, Inc. operates at 1300 York Ave, a stretch dense with medical institutions and startups alike. The company specializes in cell therapy development—harnessing endothelial cells to potentially treat degenerative diseases and accelerate tissue repair. These applications sit at the intersection of regenerative medicine and oncology, where precision matters more than scale. The neighborhood’s concentration of academic labs and investor networks makes it a logical base for firms pushing boundaries in cellular therapeutics.

Those tracking innovations in biotechnology may find the address useful; directions can be pulled from the map. To discuss partnerships or research inquiries, (877) 784-8496 connects directly to their team. The area itself remains a quiet hub of scientific activity, where sidewalks hum with the quiet rhythm of professionals moving between meetings and microscopes. No signage announces breakthroughs here—just another door in a building full of them.